Evaluación del Riesgo, Tamizaje, Diagnóstico Clínico – Patológico y Estadificación del Cáncer de Mama: 1er Consenso Nacional del Cáncer de Mama de la Sociedad Panameña de Oncología (SPO)

[Evaluación del Riesgo, Tamizaje, Diagnóstico Clínico – Patológico y Estadificación del Cáncer de Mama: 1er Consenso Nacional del Cáncer de Mama de la Sociedad Panameña de Oncología (SPO)]
DOI: 10.37980/im.journal.rmdp.2019795
Publicado
2019-07-31

Descargas

Autores/as

  • Alejandro Crismatt Zapata Instituto Oncógico Panamá Centro Hemato Oncológico Panamá
  • Joel Moreno Instituto Oncológico Nacional (ION), Panamá Centro Hemato Oncológico Panamá (CHOP), Panamá
  • Ruth M. Vergara
  • Héctor Tapia
  • Bleixen G. Admadé
  • Olivia El Achtar

Resumen

Risk Assessment, Screening, Clinical - Pathological Diagnosis and Staging of Breast Cancer: 1st National Consensus of Breast Cancer of the Panamanian Society of Oncology (SPO)

Resumen
El cáncer de Mama es el tumor más frecuente de la mujer y su incidencia va en aumento. En la atención primaria del paciente, se debe establecer el riesgo de padecer cáncer de mama durante la vida, a través de una historia clínica orientada a los factores de riesgo familiares e individuales, de tal forma que podamos implementar las estrategias de tamizaje apropiadas. Las estrategias de tamizaje deben ser aplicadas de manera sistemáticas, y los resultados anormales referidos a un centro con experiencia en el diagnóstico. Los pacientes diagnosticados deben ser evaluador por un equipo multidisciplinario con experiencia en el manejo de la muestra, estadificación y tratamiento del cáncer de mama.

Summary
Breast cancer is the most frequent tumor in women and its incidence is increasing. In the primary care of the patient, the risk of suffering from breast cancer should be established during life, through a clinical history focused on family and individual risk factors, in such a way that we can implement the appropriate screening strategies. Screening strategies should be applied systematically, and abnormal results referred to a center with experience in diagnosis. Patients diagnosed should be evaluated by a multidisciplinary team with experience in the management of the sample, staging and treatment of breast cancer.sk Assessment, Screening, Clinical - Pathological Diagnosis and Staging of Breast Cancer: 1st National Consensus of Breast Cancer of the Panamanian Society of Oncology (SPO)


Abstract

Risk Assessment, Screening, Clinical - Pathological Diagnosis and Staging of Breast Cancer: 1st National Consensus of Breast Cancer of the Panamanian Society of Oncology (SPO)

Resumen
El cáncer de Mama es el tumor más frecuente de la mujer y su incidencia va en aumento. En la atención primaria del paciente, se debe establecer el riesgo de padecer cáncer de mama durante la vida, a través de una historia clínica orientada a los factores de riesgo familiares e individuales, de tal forma que podamos implementar las estrategias de tamizaje apropiadas. Las estrategias de tamizaje deben ser aplicadas de manera sistemáticas, y los resultados anormales referidos a un centro con experiencia en el diagnóstico. Los pacientes diagnosticados deben ser evaluador por un equipo multidisciplinario con experiencia en el manejo de la muestra, estadificación y tratamiento del cáncer de mama.

Summary
Breast cancer is the most frequent tumor in women and its incidence is increasing. In the primary care of the patient, the risk of suffering from breast cancer should be established during life, through a clinical history focused on family and individual risk factors, in such a way that we can implement the appropriate screening strategies. Screening strategies should be applied systematically, and abnormal results referred to a center with experience in diagnosis. Patients diagnosed should be evaluated by a multidisciplinary team with experience in the management of the sample, staging and treatment of breast cancer.sk Assessment, Screening, Clinical - Pathological Diagnosis and Staging of Breast Cancer: 1st National Consensus of Breast Cancer of the Panamanian Society of Oncology (SPO)

Biografía del autor/a

Alejandro Crismatt Zapata, Instituto Oncógico Panamá Centro Hemato Oncológico Panamá

Sociedad Panameña de Oncología - Presidente (2016-2018)

Oncología Médica

  • ION 2010 - Actualidad: Departamento de Oncología
  • CHOP 2010 - actualidad: Oncólogo Médico.

Joel Moreno, Instituto Oncológico Nacional (ION), Panamá Centro Hemato Oncológico Panamá (CHOP), Panamá

Título de Medicina: Universidad Nacional, Panamá

Especialidad en Medicina Interna: Hospital Amador Guerrero, Colon, Panamá.

Subespecialidad en oncología Médica: Instituto oncológico Nacional

Citas

Khan F, Agarwald A, and Agrawal D. Significance of chimerism hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Transplantation (2004):34, 1-12.

Frankfurt U, Zitzner R, Tambur A. Real time qPCR for chimerism assessment in allogeneic hematopoietic stem cell transplants from unrelated adult and double umbilical cord blood. Human Immunology 2015:76:155-160

Clemente I, Goncalo C, Faria, M et. al. Relevance for Chimerism analysis after allogeneic stem cell Transplantation. Transplantation Proceeding (2017):49,890-892.

Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M., et al. Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival times. Biol Blood Marrow Transplant 2014:20(8) 1139-44.

Sellman L, Rabe K, et al. Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-018-0176-7.

Kroger N, Bacher U, Brader P, Bottcher S, Borowitz MJ, Dreger P et al. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following allogeneic Stem Cell Transplantation. Part I. Methods, acute leukemias,and myelodisplastic syndromes. Biol Blood Marrow Transplant: J Am soc Blood Marrow Transplant. 2010; 16:1187-211.

Kroger N, Bacher U, Brader P, Bottcher S, Borowitz MJ, Dreger P et al. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following allogeneic Stem Cell Transplantation. Part II: chronic leukemia’s, myeloproliferative neoplasms and lymphoid malignancies.. Biol Blood Marrow Transplant, 2010; 16:1325-46.

] Kliman D, et al. Ultra-Sensitive Droplet Digital PCR for the Assessment of Microchimerism in Cellular Therapies. Biol. Blood Marrow Transplant (2018): 24; 1069-1078.

Technical Manual. Gene prints STR Systems (Silver Stain Detection). Promega Corporation.

Global Filer PCR Amplification User Guide. Applied Biosystems. Thermo Ficher Scientific.

] Wang D., Goopinath S., Lagacé R., Norona W., Hennessy L., Short M., Mulero J. Development validation of the Global Filer Express PCR Amplificaetion Kite: a 6-dye multiplex assay for the direct amplification of reference samples. Forensic Science International. Genetics. 19(2015)148-155.

Thiede C, Florek M, et al. Rapid quantification for mixed chimerism using multiplex amplification of short tandem repeats markers and fluorescent detection. Bone Marrow Transplant 1999:23:1055-1060.

Thiede C. Quantitative analysis of chimerism after allogeneic stem cell transplantation using multiple PCR amplification of short tandem repeats markers and fluorescent detection. Leukemia (2001) 15: 302-306.